Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin Dose Escalation Trial for aHSIL in HIV Patients
NCT06626230Phase 1Recruiting
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of curcumin in anal squamous intraepithelial lesion (ASIL) (8 arms). Primary endpoint: Maximum Tolerated Dose. Started Mar 2025; status: recruiting.
02
Drugs
curcumin
03
Conditions
anal squamous intraepithelial lesion (ASIL)
Beyond the preview
Go deeper on NCT06626230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626230.